Sequential emergence of ABL-kinase mutations with loss of unmutated BCR-ABL allele during targeted therapies of CML

MeSH terms

• Aged
• Antineoplastic Agents
• Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
• Benzamides
• Dasatinib
• Fusion Proteins, bcr-abl / genetics*
• Genes, abl*
• Humans
• Imatinib Mesylate
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive / enzymology
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics*
• Mutation*
• Piperazines / administration & dosage
• Pyrimidines / administration & dosage
• Thiazoles / administration & dosage